|Min SIP Amount||₹1000|
|NAV||₹62.67 (23 Oct 2020)|
|Fund Started||07 Jan 2013|
|Fund Size||₹49 Cr|
|Strides Pharma Science Ltd.||Healthcare||Equity||8.4%|
|Stylam Industries Ltd.||FMCG||Equity||6.7%|
|Caplin Point Laboratories Ltd.||Healthcare||Equity||6.0%|
|PTC India Financial Services Ltd.||Financial||Equity||5.4%|
|Sumitomo Chemical India Pvt. Ltd.||Others||Equity||5.2%|
|Bharti Airtel Ltd.||Communication||Equity||4.8%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||4.0%|
|Bharat Rasayan Ltd.||Chemicals||Equity||3.7%|
Quant Small Cap Fund Direct Plan Growth is a Hybrid Mutual Fund Scheme launched by Quant Mutual Fund. This scheme was made available to investors on 07 Jan 2013. Pushpa Rai is the Current Fund Manager of Quant Small Cap Fund Direct Plan Growth fund.The fund currently has an Asset Under Management(AUM) of ₹49 Cr and the Latest NAV as of 23 Oct 2020 is ₹62.67.
The Quant Small Cap Fund Direct Plan Growth is rated Moderately High risk. Minimum SIP Investment is set to 1000. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year
The scheme seeks to generate capital appreciation by investing in a well-diversified portfolio of small cap companies.
Returns are taxed as per your Income Tax slab, if sold before 3 years. Negligible Tax (20% with indexation benefit) post 3 years.